[go: up one dir, main page]

MX2016008345A - Produccion de anticuerpos ex vivo. - Google Patents

Produccion de anticuerpos ex vivo.

Info

Publication number
MX2016008345A
MX2016008345A MX2016008345A MX2016008345A MX2016008345A MX 2016008345 A MX2016008345 A MX 2016008345A MX 2016008345 A MX2016008345 A MX 2016008345A MX 2016008345 A MX2016008345 A MX 2016008345A MX 2016008345 A MX2016008345 A MX 2016008345A
Authority
MX
Mexico
Prior art keywords
antibody production
vivo antibody
vivo
producing
methods
Prior art date
Application number
MX2016008345A
Other languages
English (en)
Other versions
MX386674B (es
Inventor
Beaumont Tim
Jeroen Kwakkenbos Mark
Spits Hergen
Maria Wilhelmina Van Helden Paula
Original Assignee
Aimm Therapeutics Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aimm Therapeutics Bv filed Critical Aimm Therapeutics Bv
Publication of MX2016008345A publication Critical patent/MX2016008345A/es
Publication of MX386674B publication Critical patent/MX386674B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/108—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)

Abstract

La presente invención proporciona medios y métodos para producir cultivos de células B ex vivo con un tiempo de duplicación corto.
MX2016008345A 2013-12-24 2014-12-24 Produccion de anticuerpos ex vivo. MX386674B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13199584 2013-12-24
PCT/NL2014/050908 WO2015099534A1 (en) 2013-12-24 2014-12-24 Ex vivo antibody production

Publications (2)

Publication Number Publication Date
MX2016008345A true MX2016008345A (es) 2017-02-08
MX386674B MX386674B (es) 2025-03-19

Family

ID=49885067

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008345A MX386674B (es) 2013-12-24 2014-12-24 Produccion de anticuerpos ex vivo.

Country Status (15)

Country Link
US (3) US20170009205A1 (es)
EP (2) EP4141108A1 (es)
JP (1) JP6832705B2 (es)
CN (1) CN106029873A (es)
AU (1) AU2014370516B9 (es)
BR (1) BR112016014881B1 (es)
CA (1) CA2934660C (es)
DK (1) DK3087177T3 (es)
EA (1) EA201691112A1 (es)
ES (1) ES2927905T3 (es)
HU (1) HUE060145T2 (es)
IL (1) IL246409B (es)
MX (1) MX386674B (es)
SG (1) SG11201605126YA (es)
WO (1) WO2015099534A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9206247B2 (en) * 2010-12-02 2015-12-08 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
CN116554353B (zh) * 2023-04-28 2024-05-03 北京奇迈永华生物科技有限公司 一种假病毒高效感染人nk细胞及其他免疫细胞的方法
CN118459577B (zh) * 2024-07-09 2024-11-12 浙江康佰裕生物科技有限公司 逆转录包膜蛋白GALV env蛋白及其抗体的制备

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100340668C (zh) 2002-04-26 2007-10-03 国家健康医学研究所 改进的嵌合糖蛋白和假型化慢病毒载体
ES2347979T3 (es) 2005-08-03 2010-11-26 Therapeutic Human Polyclonals, Inc. Supresion de la apoptosis en linfocitos b en animales transgenicos que expresan inmunoglobulina humanizada.
EP2540820B1 (en) 2005-12-09 2018-01-10 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for influencing the stability of antibody producing cells
AU2010271583B2 (en) 2009-07-15 2015-02-12 Kling Biotherapeutics B.V. Means and methods for producing high affinity antibodies
ES2434256T3 (es) * 2010-05-28 2013-12-16 F. Hoffmann-La Roche Ag Método de cultivo de células B individuales y producción de anticuerpos específicos
US9206247B2 (en) * 2010-12-02 2015-12-08 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
SG10201608341XA (en) * 2011-11-23 2016-11-29 Hoffmann La Roche Cd40l expressing mammalian cells and their use
WO2014109696A1 (en) * 2013-01-10 2014-07-17 Alf Grandien Method for immortalization of b cells and uses thereof
US10611829B2 (en) * 2014-01-31 2020-04-07 Aimm Therapeutics B.V. Means and methods for producing stable antibodies

Also Published As

Publication number Publication date
ES2927905T3 (es) 2022-11-11
NZ722156A (en) 2021-08-27
US20170009205A1 (en) 2017-01-12
BR112016014881A8 (pt) 2020-06-09
MX386674B (es) 2025-03-19
CA2934660A1 (en) 2015-07-02
JP6832705B2 (ja) 2021-02-24
JP2017500052A (ja) 2017-01-05
IL246409B (en) 2022-01-01
BR112016014881A2 (pt) 2017-08-08
IL246409A0 (en) 2016-08-31
AU2014370516B2 (en) 2021-03-11
SG11201605126YA (en) 2016-07-28
DK3087177T3 (da) 2022-10-03
EP3087177A1 (en) 2016-11-02
EP3087177B1 (en) 2022-09-14
US20200149007A1 (en) 2020-05-14
BR112016014881B1 (pt) 2023-03-28
AU2014370516B9 (en) 2021-07-29
EP4141108A1 (en) 2023-03-01
HUE060145T2 (hu) 2023-02-28
WO2015099534A1 (en) 2015-07-02
US20240425566A1 (en) 2024-12-26
AU2014370516A1 (en) 2016-07-07
CA2934660C (en) 2023-03-14
CN106029873A (zh) 2016-10-12
US12084681B2 (en) 2024-09-10
EA201691112A1 (ru) 2017-01-30

Similar Documents

Publication Publication Date Title
NI201400061A (es) Anticuerpos anti - phf - tau y sus usos
CO7151527A2 (es) Anticuerpos anti-cd79 b e inmunoconjugados
CR20150048A (es) Anticuerpos e inmunoconjugados anti-cd22
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
ECSP13012859A (es) Anticuerpos del cea
MY172867A (en) Bispecific egfr/c-met antibodies
UY4175Q (es) Reloj pulsera
BR112014010433A2 (pt) método e máquina para produzir uma cápsula de uso único para bebidas e cápsula obtida com o método
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
UY4151Q (es) Vincha con auriculares
CO7151529A2 (es) Anticuerpos anti-cd22 e inmunoconjugados
UY34547A (es) Un Escenario de Elevación Compuesto
UY4153Q (es) Batería
UY34167A (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
UY34127A (es) ?zapato con plantilla reconfigurable y método
UY4152Q (es) Batería
MX2016008345A (es) Produccion de anticuerpos ex vivo.
UY34150A (es) Cristal de compuesto heterociclico fusionado
UY34638A (es) Empaque normalizado y método para su elaboración.
MY167578A (en) Novel cheese and method for producing the same
BR112017012695A2 (pt) biorreator e processo de fermentação para produção de hidrogênio
MX2015009565A (es) Proceso para elaborar derivados de magnolol.
SG11201508796SA (en) Method for producing induced pluripotent stem cell from mesenchymal stem cell and induced pluripotent stem cell produced by the method
CR20150259A (es) Anticuerpos egfr/c-met biespecíficos